Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acer MedicalROCO:6857 -0.22%52 EBIT per Share is NT$-1.95 as of Dec. 2025. GuruFocus rates ROCO:6857 with a GF Score™ of 52/100 and a GF Value™ of NT$264.59 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 525 Healthcare Providers & Services companies, Acer Medical ranks better than 64% on this metric.
Acer Medical's EBIT per Share for the
six
months ended in Dec. 2025 was NT$-0.86.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1.95.
During the past 3 years, the average EBIT per Share Growth Rate was 21.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 4.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Acer Medical's EBIT per Share or its related term are showing as below:
ROCO:6857'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -59.4 Med: 1.9 Max: 21.7
Current: 21.7
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Acer Medical was 21.70% per year. The lowest was -59.40% per year. And the median was 1.90% per year.
ROCO:6857's 3-Year EBIT Growth Rate is ranked better than 64% of 525
companies
in the Healthcare Providers & Services industry
Industry Median: 12
vs ROCO:6857: 21.70
Acer Medical's EBIT for the
six
months ended in Dec. 2025 was NT$-13.07 Mil.
Acer Medical (ROCO:6857) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Acer Medical EBIT per Share Related Terms
Acer Medical EBIT per Share Historical Data
* Premium members only.
The historical data trend for Acer Medical's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-1.95
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acer Medical (ROCO:6857) has a EBIT per Share of NT$-1.95 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Acer Medical and its competitors. According to the industry distribution chart, Acer Medical ranks #189 out of 525 companies in the Healthcare Providers & Services industry, placing it in the top 36%.
Is Acer Medical's EBIT per Share too high?
Acer Medical's current EBIT per Share is NT$-1.95. Based on the distribution chart, Acer Medical ranks #189 out of 525 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Acer Medical has a GF Score™ of 52/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Acer Medical's EBIT per Share compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Acer Medical ranks #189 out of 525 companies for EBIT per Share. This puts Acer Medical in the upper half of its industry. The industry median EBIT per Share is 12.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 12.00, based on 525 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Acer Medical and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 12.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acer Medical's current EBIT per Share is NT$-1.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acer Medical stock overvalued right now?
Based on GuruFocus' analysis, Acer Medical (ROCO:6857) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$264.59, compared to a current price of NT$92.50 — trading 65% below its estimated fair value. The current EBIT per Share is NT$-1.95. Acer Medical's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Acer Medical (ROCO:6857), the current EBIT per Share is NT$-1.95 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acer Medical (ROCO:6857) Overvalued in 2026?
Based on GuruFocus' analysis, Acer Medical stock appears to be undervalued.
The current stock price of NT$92.50 is trading 65% below its estimated GF Value™ of NT$264.59.
GuruFocus considers Acer Medical to be Significantly Undervalued.
Key valuation signals for ROCO:6857:
EBIT per Share: NT$-1.95
GF Value™: NT$264.59 vs. price of NT$92.50 (65% below fair value)
No single metric tells the full story. See the ROCO:6857 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acer Medical Inc focuses on improving human health and well-being through artificial intelligence. It focuses on applying artificial intelligence and large data to the area of healthcare. Acer Medical is capable of designing, developing, commercializing, as well as implementing AI solutions in medical institutions.
52GF Score
Get the complete analysis for ROCO:6857
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6857 has been successfully added to your 
